Valuation: Brooks Laboratories Limited

Market Cap 1.09B 11.34M 9.92M 9.17M 8.42M 15.93M 16.2M 109M 42.96M 534M 42.6M 41.67M 1.84B P/E 2024
-12.2x
P/E 2025 -28.6x
Enterprise Value 1.17B 12.13M 10.6M 9.8M 9M 17.03M 17.32M 117M 45.93M 571M 45.54M 44.54M 1.97B EV / Sales 2024
3.16x
EV / Sales 2025 3.93x
Free-Float
43.99%
Yield 2024 *
-
Yield 2025 -
02:21pm Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
06-18 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-06 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/10/25 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
13/08/25 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
28/05/25 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
13/02/25 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
26/12/24 Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024 CI
10/12/24 Brooks Laboratories Limited announced that it expects to receive INR 750 million in funding from Jalan Chemical Industries Private Limited, K M Visaria Family Trust CI
1 day-0.77%
1 week-2.67%
Current month+0.59%
1 month+3.21%
3 months+2.00%
6 months+1.43%
Current year-13.57%
1 week 68.1
Extreme 68.1
72.99
1 month 66.53
Extreme 66.53
79
Current year 36.9
Extreme 36.9
82.3
1 year 36.9
Extreme 36.9
165.95
3 years 36.9
Extreme 36.9
202.8
5 years 36.9
Extreme 36.9
202.8
10 years 14.05
Extreme 14.05
202.8
Manager TitleAgeSince
Chief Executive Officer - 31/05/2026
President 57 22/08/2023
Compliance Officer 33 25/12/2024
Director TitleAgeSince
Director/Board Member 53 22/11/2022
Director/Board Member 62 09/09/2010
Director/Board Member - 22/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%-2.67% - - 21.33M
-0.90%-0.15%+13.46%+79.34% 48.56B
-0.23%-1.65%+65.14%+112.03% 35.65B
-0.76%-1.44%-4.30%+37.38% 11.98B
-0.88%-0.62%+16.38%+89.65% 11.95B
+1.68%+1.90%+34.67%+129.06% 9.29B
-0.91%-1.08%+18.07%+37.00% 6.95B
+3.37%-0.10%+49.31%-3.75% 6.79B
-2.25%-2.08%+0.40%+218.27% 6.7B
+7.04%+17.50%-14.38%+29.12% 6.81B
Average +0.54%+1.14%+19.86%+80.90% 16.07B
Weighted average by Cap. -0.05%+0.57%+26.31%+86.10%

Financials

2024 2025
Net sales 795M 8.25M 7.21M 6.67M 6.12M 11.58M 11.78M 79.52M 31.24M 388M 30.98M 30.3M 1.34B 826M 8.57M 7.49M 6.93M 6.36M 12.03M 12.24M 82.6M 32.45M 403M 32.17M 31.47M 1.39B
Net income -196M -2.03M -1.78M -1.64M -1.51M -2.85M -2.9M -19.6M -7.7M -95.67M -7.64M -7.47M -330M -99.67M -1.03M -904K -836K -767K -1.45M -1.48M -9.97M -3.92M -48.67M -3.88M -3.8M -168M
Net Debt 55.16M 572K 500K 463K 425K 804K 818K 5.52M 2.17M 26.94M 2.15M 2.1M 93M 75.39M 782K 684K 632K 580K 1.1M 1.12M 7.54M 2.96M 36.82M 2.94M 2.87M 127M
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
Employees
323
Date Price Change Volume
17/07/26 69.36 -0.77% 2,579
16/07/26 ₹69.90 -1.13% 430
15/07/26 ₹70.70 -1.68% 1,024
14/07/26 ₹71.91 +2.76% 5,580
13/07/26 ₹69.98 -1.80% 2,380